Transplantation: Does anemia correction delay kidney allograft dysfunction?

Edmund Huang, Suphamai Bunnapradist

Research output: Contribution to journalShort surveypeer-review

1 Scopus citations


In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.

Original languageEnglish (US)
Pages (from-to)196-198
Number of pages3
JournalNature Reviews Nephrology
Issue number4
StatePublished - Apr 2012

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Transplantation: Does anemia correction delay kidney allograft dysfunction?'. Together they form a unique fingerprint.

Cite this